TIDMRUA

RNS Number : 2352W

RUA Life Sciences PLC

16 August 2022

16 August 2022

RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Result of AGM

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ), announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 
  Res No.      Votes        %          Votes Against     %       Votes Total   % I.S.C.     Votes 
                For                                                                          Withheld 
    01       2,517,502   100.00%           0            0.00%     2,517,502     11.35        11,763 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    02       1,164,389   96.51%           42,142        3.49%     1,206,531      5.44      1,322,734 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    03       2,517,502   100.00%           0            0.00%     2,517,502     11.35        11,763 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    04       2,517,502   100.00%           0            0.00%     2,517,502     11.35        11,763 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    05       1,900,843   94.80%          104,178        5.20%     2,005,021      9.04       524,244 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    06       2,413,324   95.86%          104,178        4.14%     2,517,502     11.35        11,763 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    07       2,517,487   100.00%            15          0.00%     2,517,502     11.35        11,763 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    08       2,508,972   99.66%           8,530         0.34%     2,517,502     11.35        11,763 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    09       2,404,481   95.51%          112,921        4.49%     2,517,402     11.35        11,863 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
    10       2,404,385   95.51%          112,921        4.49%     2,517,306     11.35        11,959 
           -----------  --------  ------------------  -------  -------------  ---------  ------------ 
 

For further information contact:

RUA Life Sciences

Bill Brown, Chairman Tel: +44 (0)1294 317073

   Dr Caroline Stretton, Group MD                                            Tel: +44 (0)1294 317073 
   Cenkos Securities plc (Nominated Adviser and Broker)    Tel: +44 (0)20 7397 8900 

Giles Balleny/Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon(TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical:        End-to-end contract developer and manufacturer 
                      of medical devices and implantable fabric 
                      specialist. 
 RUA Biomaterials:   Licensor of Elast-Eon(TM) polymers to the 
                      medical device industry. 
 RUA Vascular:       Commercialisation of open surgical vascular 
                      grafts and patches 
 RUA Structural      Development of polymeric leaflet systems 
  Heart:              for heart valves. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGPFMRTMTMBBAT

(END) Dow Jones Newswires

August 16, 2022 13:06 ET (17:06 GMT)

Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 2 2024 まで 3 2024 Rua Life Sciencesのチャートをもっと見るにはこちらをクリック
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 3 2023 まで 3 2024 Rua Life Sciencesのチャートをもっと見るにはこちらをクリック